– UK, Abingdon / USA, MA – Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it has appointed Patrick J. Balthrop, Sr. as Chairman of its board of directors. The current Chairman, Mr Richard A. Sandberg, will remain a member of the board.
“We are very pleased to have Mr Balthrop assume the role of Chairman,” said Dr Peter Wrighton-Smith, CEO of Oxford Immunotec. “
“Mr Balthrop brings a vast array of skills to the role of chair, including his extensive knowledge of the diagnostics and life sciences industries and his experience as both a Chairman and a member of multiple boards. In his role as a Non-Executive Director over the past three years, Mr. Balthrop has built a deep understanding of the Company and demonstrated the value of his broad leadership experience,” he added.
“On behalf of the Company and the board of directors I would like to thank our former Chairman, Richard Sandberg, for his service,” continued Dr Peter Wrighton-Smith. “In the decade that he served as Chairman, the Company has undergone a profound transformation, and Mr Sandberg’s guidance and leadership has made an extraordinary contribution to Oxford Immunotec’s success. We look forward to continuing to benefit from his skills and his knowledge of the Company with his ongoing service as a Non-Executive Director.”
About Patrick J. Balthrop, Sr.
Mr Balthrop currently serves as Chairman of the board of directors of Agendia, Inc., personalised medicine and molecular cancer diagnostics company, and as Chairman of the board of directors of Discovery Life Sciences, a premier provider of research services and biospecimen solutions to the life sciences industry. He is also a member of the board of directors of Personalis, Inc. (NASDAQ: PSNL) a provider of advanced genomic sequencing and analytics for immuno-oncology, and an Executive Advisor for Water Street Healthcare Partners, strategic investors who specialize in growing middle-market healthcare companies.
Mr Balthrop served as President and CEO of Luminex Corporation from 2004 to 2014, during which time the company’s revenues grew eightfold. Before joining Luminex, he served as President of Fisher Healthcare, which is now a division of Thermo Fisher Scientific, Inc. Mr Balthrop also held multiple positions at Abbott Laboratories, where he played an integral part in the development and global commercialization of a number of high profile diagnostic products.
Mr Balthrop earned his bachelor’s degree in Biology from Spring Hill College and his Master of Business Administration from the Kellogg School of Management at Northwestern University.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company’s T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA.
For more information: http://www.oxfordimmunotec.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.